Hydrophilic carbon clusters as therapeutic, high-capacity antioxidants

Trends in Biotechnology

Volumn 32, Issue 10, 2014, Pages 501-505

  Samuel, Errol L G ^a   Duong, MyLinh T ^a   Bitner, Brittany R ^b   Marcano, Daniela C ^a   Tour, James M ^a,c   Kent, Thomas A ^b,d  

^a RICE UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c RICE UNIVERSITY   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antioxidant; Carbon nanoparticle; Oxidative stress; Traumatic brain injury

Indexed keywords

BRAIN; CARBON CLUSTERS; HYDROPHILICITY; NANOPARTICLES; NITRIC OXIDE; OXIDATIVE STRESS; OXYGEN; PATHOLOGY; POLYETHYLENE GLYCOLS;

CARBON NANO-PARTICLES; CLINICAL TRIAL; FUNCTIONALIZED; HIGH CAPACITY; HUMAN PATHOLOGIES; HYDROPHILIC CARBON CLUSTERS; REACTIVE OXYGEN SPECIES; TRAUMATIC BRAIN INJURIES;

ANTIOXIDANTS;

ANTIOXIDANT; CARBON; ENZYME; HYDROXYL RADICAL; MACROGOL; NANOPARTICLE; NITRIC OXIDE; OXYGEN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

ANTIOXIDANT ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SYNTHESIS; EXPERIMENTAL MODEL; HUMAN; HYDROPHILICITY; MULTICENTER STUDY (TOPIC); NONHUMAN; OXIDATIVE STRESS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; BIOTECHNOLOGY; CHEMICAL PHENOMENA; NANOTECHNOLOGY;

ANTIOXIDANTS; BIOTECHNOLOGY; CARBON; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; NANOTECHNOLOGY; OXIDATIVE STRESS;

EID: 84908038008     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2014.08.005     Document Type: Review

References (42)

1. Fucci L., et al. Inactivation of key metabolic enzymes by mixed-function oxidation reactions: possible implication in protein turnover and ageing. Proc. Natl. Acad. Sci. U.S.A. 1983, 80:1521-1525.
2. Valko M., et al. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
3. Miller D.M., et al. Transition metals as catalysts of 'autoxidation' reactions. Free Radic. Biol. Med. 1990, 8:95-108.
4. •: in vitro and in vivo. Free Radic. Biol. Med. 1994, 16:29-33.
5. Radi R., et al. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch. Biochem. Biophys. 1991, 288:481-487.
6. Deng-Bryant Y., et al. Neuroprotective effects of tempol, a catalytic scavenger of peroxynitrite-derived free radicals, in a mouse traumatic brain injury model. J. Cereb. Blood Flow Metab. 2008, 28:1114-1126.
7. Fridovich I. Superoxide dismutases. Annu. Rev. Biochem. 1975, 44:147-159.
8. Evans C.A.L. On the catalytic decomposition of hydrogen peroxide by the catalase of blood. Biochem. J. 1907, 2:133-155.
9. Kokubo Y., et al. Transgenic mice expressing human copper-zinc superoxide disumtase exhibit attenuated apparent diffusion coefficient reduction during reperfusion following focal cerebral ischemia. Brain Res. 2002, 947:1-8.
10. Slemmer J.E., et al. Antioxidants and free radical scavengers for the treatment of stroke, traumatic brain injury and aging. Curr. Med. Chem. 2008, 15:404-414.
11. Schubert D., et al. Cerium and yttrium oxide nanoparticles are neuroprotective. Biochem. Biophys. Res. Commun. 2006, 342:86-91.
12. Kajita M., et al. Platinum nanoparticle is a useful scavenger of superoxide anion and hydrogen peroxide. Free Radic. Res. 2007, 41:615-626.
13. Martínez A., Galano A. Free radical scavenging activity of ultrashort single-walled carbon nanotubes with different structures through electron transfer reactions. J. Phys. Chem. C 2010, 114:8184-8191.
14. 60. Science 1991, 254:1183-1185.
15. Dugan L.L., et al. Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons. Neurobiol. Dis. 1996, 3:129-135.
16. 60) derivative with superoxide dismutase mimetic properties. Free Radic. Biol. Med. 2004, 37:1191-1202.
17. n (n=2-6). Free Radic. Biol. Med. 2000, 29:26-33.
18. Lucente-Schultz R.M., et al. Antioxidant single-walled carbon nanotubes. J. Am. Chem. Soc. 2009, 131:3934-3941.
19. Galano A. Carbon nanotubes: promising agents against free radicals. Nanoscale 2010, 2:373-380.
20. Liu Y., et al. Understanding the toxicity of carbon nanotubes. Acc. Chem. Res. 2013, 46:702-713.
21. Berlin J.M., et al. Effective drug delivery, in vitro and in vivo, by carbon-based nanovectors noncovalently loaded with unmodified paclitaxel. ACS Nano 2010, 4:4261-4636.
22. Berlin J.M., et al. Noncovalent functionalization of carbon nanovectors with an antibody enables targeted drug delivery. ACS Nano 2011, 5:6643-6650.
23. Sano D., et al. Noncovalent assembly of targeted carbon nanovectors enables synergistic drug and radiation cancer therapy in vivo. ACS Nano 2012, 6:2497-2505.
24. Sharpe M.A., et al. Antibody-targeted nanovectors for the treatment of brain cancers. ACS Nano 2012, 6:3114-3120.
25. Marcano D.C., et al. Design of poly(ethylene glycol)-functionalized hydrophilic carbon clusters for targeted therapy of cerebrovascular dysfunction in mild traumatic brain injury. J. Neurotrauma 2013, 30:789-796.
26. Bitner B.R., et al. Antioxidant carbon particles improve cerebrovasculate dysfunction following traumatic brain injury. ACS Nano 2012, 6:8007-8014.
27. Berlin J.M., Tour J.M. Development of novel drug delivery vehicles. Nanomedicine (Lond.) 2010, 5:1487-1489.
28. Hurt R.H., et al. Toxicology of carbon nanomaterials: status, trends, and perspectives on the special issue. Carbon 2006, 44:1028-1033.
29. Sayes C.M., et al. Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro. Toxicol. Lett. 2006, 161:135-142.
30. Schipper M.L., et al. A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice. Nat. Nanotechnol. 2008, 3:216-221.
31. Wanka L., et al. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem. Rev. 2013, 113:3516-3604.
32. Allen B.L., et al. Biodegradation of single-walled carbon nanotubes through enzymatic catalysis. Nano Lett. 2008, 8:3899-3903.
33. Kagan V.E., et al. Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation. Nat. Nanotechnol. 2010, 5:354-359.
34. Hall E.D., et al. Antioxidant therapies for traumatic brain injury. Nanotherapeutics 2010, 7:51-61.
35. Fabian R.H., et al. In vivo detection of superoxide anion production by the brain using a cytochrome c electrode. J. Cereb. Blood Flow Metab. 1995, 15:242-247.
36. Chesnut R.M., et al. The role of secondary brain injury in determining outcome from severe head injury. J. Trauma 1993, 34:216-222.
37. Marshall L.F., et al. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. J. Neurosurg. 1998, 89:519-525.
38. Muizelaar J.P., et al. PEG-SOD after head injury. J. Neurosurg. 1995, 83:942.
39. Razmkon A., et al. Administration of vitamin C and vitamin E in severe head injury: a randomized double-blind controlled trial. Clin. Neurosurg. 2011, 58:133-137.
40. Maas A.I.R., et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a Phase III double-blind controlled trial. Lancet Neurol. 2006, 5:38-45.
41. Phillips D.C., et al. Aberrant reactive oxygen and nitrogen species generation in rheumatoid arthritis (RA): causes and consequences for immune function, cell survival, and therapeutic intervention. Antioxid. Redox Signal. 2010, 12:743-785.
42. Uttara B., et al. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 2009, 7:65-74.